Commercial Scale Up and Financials Report
Overview Market Opportunity Product Line & Evidence
Commercial Scale Up Insurance Reimbursement
Financials
Capital Requirements and Cash Flow Breakeven
myomo
my own motion
It is achievable to be cash flow breakeven on a quarterly basis by the fourth
quarter of 2024. Requirements:
Final published fees by CMS for the MyoPro product line are not
significantly lower than the currently published preliminary fees.
We are able to add clinical, manufacturing and reimbursement capacity to
serve additional volume as planned.
No unforeseen supply chain disruptions impacting deliveries and revenue
Assuming the above, we believe our existing cash plus the net proceeds
received from the recently completed offering would be sufficient to achieve
cash flow breakeven and no additional equity capital would be required for
liquidity.
21View entire presentation